ABT

Abbott Laboratories

Add to Watchlist

Advanced Chart

125.940

+0.3(0.239%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

126.500

Open

125.770

VWAP

125.97

Vol

1.53M

Mkt Cap

218.59B

Low

125.496

Amount

192.69M

EV/EBITDA(TTM)

22.35

Total Shares

1.74B

225.57B

EV/OCF(TTM)

P/S(TTM)

5.10

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

11.25B

+8.65%

1.222

+12.13%

11.77B

+7.29%

1.487

+10.99%

11.40B

+7.17%

1.299

+7.39%

Estimates Revision

The market is revising Upward the revenue expectations for Abbott Laboratories (ABT) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by -2.26%.

Revenue Estimates for FY2025

Revise Upward

+0.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

Stock Price

Go Down

-2.26%

In Past 3 Month

21 Analyst Rating

13.97% Upside

Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 143.53 USD with a low forecast of 127.00 USD and a high forecast of 159.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

4 Hold

0 Sell

Strong Buy

13.97% Upside

Current: 125.940

Low

127.00

Averages

143.53

High

159.00

13.97% Upside

Current: 125.940

Low

127.00

Averages

143.53

High

159.00

Jefferies

Matthew Taylor

Hold

Buy

upgrade

$143 -> $145

2025-07-18

Reason

Jefferies

Matthew Taylor

Price Target

$143 -> $145

2025-07-18

upgrade

Hold

Buy

Reason

Jefferies analyst Matthew Taylor upgraded Abbott to Buy from Hold with a price target of $145, up from $143. The firm says that while Abbott's Q2 report and outlook were "underwhelming," the corresponding share selloff is "too punitive." Jefferies recommends taking advantage of the pullback as it believes the company's growth can accelerate in 2026. The stock's current valuation is "compelling for a quality franchise with multiple growth drivers," the analyst tells investors in a research note.

Wells Fargo

Overweight

NULL

downgrade

$147 -> $142

2025-07-18

Reason

Wells Fargo

Price Target

$147 -> $142

2025-07-18

downgrade

Overweight

NULL

Reason

Wells Fargo lowered the firm's price target on Abbott to $142 from $147 and keeps an Overweight rating on the shares after the company reported about in-line Q2 sales and EPS. Abbott lowered 2025 organic sales growth guide due to transitory headwinds in Dx and narrowed its EPS guide. The firm believes the 2026 outlook is intact.

Mizuho

Neutral

downgrade

$140 -> $135

2025-07-18

Reason

Mizuho

Price Target

$140 -> $135

2025-07-18

downgrade

Neutral

Reason

Mizuho lowered the firm's price target on Abbott to $135 from $140 and keeps a Neutral rating on the shares following the Q2 report. The firm cut estimates on the sales guidance revision. The share selloff may be overdone but a potential rebound may be gradual, the analyst tells investors in a research note.

Raymond James

Outperform

maintain

$142 -> $141

2025-07-18

Reason

Raymond James

Price Target

$142 -> $141

2025-07-18

maintain

Outperform

Reason

Raymond James lowered the firm's price target on Abbott to $141 from $142 and keeps an Outperform rating on the shares. Abbott's Q2 results were strong in Med Devices, but idiosyncratic issues are weighing on Diagnostics growth, which is slowing Abbott's momentum, the analyst tells investors in a research note. The firm views these issues as transient.

Mizuho

Neutral

maintain

$130 -> $140

2025-07-16

Reason

Mizuho

Price Target

$130 -> $140

2025-07-16

maintain

Neutral

Reason

Mizuho raised the firm's price target on Abbott to $140 from $130 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

Morgan Stanley

Equal Weight

maintain

$127 -> $137

2025-07-15

Reason

Morgan Stanley

Price Target

$127 -> $137

2025-07-15

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Abbott to $137 from $127 and keeps an Equal Weight rating on the shares. The firm continues to like the industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Abbott Laboratories (ABT.N) is 23.23, compared to its 5-year average forward P/E of 24.69. For a more detailed relative valuation and DCF analysis to assess Abbott Laboratories 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

24.69

Current PE

23.23

Overvalued PE

26.90

Undervalued PE

22.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

18.93

Current EV/EBITDA

17.99

Overvalued EV/EBITDA

20.26

Undervalued EV/EBITDA

17.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.85

Current PS

4.71

Overvalued PS

5.27

Undervalued PS

4.42

Financials

Annual

Quarterly

FY2025Q2

YoY :

+7.37%

11.14B

Total Revenue

FY2025Q2

YoY :

+19.55%

2.07B

Operating Profit

FY2025Q2

YoY :

+36.64%

1.78B

Net Income after Tax

FY2025Q2

YoY :

+37.84%

1.02

EPS - Diluted

FY2025Q1

YoY :

+48.80%

933.00M

Free Cash Flow

FY2025Q2

YoY :

+2.55%

52.67

Gross Profit Margin - %

FY2025Q2

YoY :

+27.25%

15.97

Net Margin - %

FY2025Q2

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

50.5M

USD

6-9

Months

27.7M

USD

0-12

Months

34.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 2492.66% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

4.9M

Volume

6-9

Months

190.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

379.7K

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

215.0K

USD

3-6

Months

40.0K

USD

6-9

Months

105.0K

USD

0-12

Months

8.0K

USD

Bought

0-3

0.0

USD

Months

3-6

40.0K

USD

Months

6-9

123.0K

USD

Months

0-12

8.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

50.5M

USD

6-9

Months

27.7M

USD

0-12

Months

34.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABT News & Events

Events Timeline

2025-07-17 (ET)

2025-07-17

09:23:18

Abbott sees Q3 EPS $1.28-$1.32, consensus $1.33

2025-07-17

08:29:56

Abbott down 5% at $125.40 after Q2 results, narrowed FY25 outlook

2025-07-17

07:32:22

Abbott narrows FY25 adjusted EPS view to $5.10-$5.20 from $5.05-$5.25

News

5.0

15:13 PMYahoo Finance

Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic

6.5

07-24NASDAQ.COM

The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple

5.0

07-24CNBC

This Indian pharma company sees a big opportunity in generic versions of weight-loss drugs